Julie Kanter

6.9k total citations · 1 hit paper
192 papers, 3.6k citations indexed

About

Julie Kanter is a scholar working on Genetics, Hematology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Julie Kanter has authored 192 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 166 papers in Genetics, 120 papers in Hematology and 64 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Julie Kanter's work include Hemoglobinopathies and Related Disorders (166 papers), Iron Metabolism and Disorders (105 papers) and Prenatal Screening and Diagnostics (50 papers). Julie Kanter is often cited by papers focused on Hemoglobinopathies and Related Disorders (166 papers), Iron Metabolism and Disorders (105 papers) and Prenatal Screening and Diagnostics (50 papers). Julie Kanter collaborates with scholars based in United States, United Kingdom and France. Julie Kanter's co-authors include Abdullah Kutlar, Rebecca Kruse‐Jarres, Xiaoxi Yang, Victor R. Gordeuk, Kenneth I. Ataga, Darla Liles, Ofelia Álvarez, Jennifer Knight‐Madden, Rodolfo Delfini Cançado and João Ricardo Friedrisch and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and SHILAP Revista de lepidopterología.

In The Last Decade

Julie Kanter

175 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

2016 595 citations Kenneth I. Ataga, Abdullah Kutlar et al. profile →

Peers

Countries citing papers authored by Julie Kanter

Since Specialization

Citations

This map shows the geographic impact of Julie Kanter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Kanter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Kanter more than expected).

Fields of papers citing papers by Julie Kanter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Kanter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Kanter. The network helps show where Julie Kanter may publish in the future.

Co-authorship network of co-authors of Julie Kanter

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Kanter. A scholar is included among the top collaborators of Julie Kanter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Kanter. Julie Kanter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mortality in adults with sickle cell disease: Results from the sickle cell disease implementation consortium (SCDIC) registry 2024 ·American Journal of Hematology ·(unknown), Norma Pugh, Donald Brambilla, Barbara L. Kroner, Nirmish Shah, Marsha Treadwell, Robert W. Gibson, Lewis L. Hsu, Victor R. Gordeuk, Jeffrey Glassberg, Jane S. Hankins, Abdullah Kutlar, Allison A. King, Julie Kanter	9
2	Costs and impact of disease in adults with sickle cell disease: a pilot study 2024 ·Blood Advances ·Sophie Lanzkron, (unknown), Joanne Wu, (unknown), Randall Curtis, Derek Robertson, Judith Baker, Diane J. Nugent, Amit Soni, Jonathan Roberts, Megan M. Ullman, Julie Kanter, Michael B. Nichol	4
3	Motixafortide for Hematopoietic Stem and Progenitor Cell Mobilization and Collection in Sickle Cell Disease 2024 ·Blood ·Alexis Leonard, Akshay Sharma, Yogindra Persaud, (unknown), Danielle L Pickett, R U Massey, (unknown), (unknown), Salem Akel, (unknown), Yan Zheng, Ella Sorani, (unknown), Mitchell J. Weiss, Stephen Gottschalk, Julie Kanter, Matthew M. Hsieh, John F. Tisdale	2
4	Short-term air pollution levels and sickle cell disease hospital encounters in South Carolina: A case-crossover analysis 2024 ·Environmental Research ·Tong Wen, Robin Puett, Duanping Liao, Julie Kanter, Murray A. Mittleman, Sophie Lanzkron, Jeff D. Yanosky	2
5	Iron restriction in sickle cell disease: When less is more 2024 ·American Journal of Hematology ·Oswaldo Castro, Lucia De Franceschi, Tomas Ganz, Julie Kanter, Gregory J. Kato, Sant‐Rayn Pasricha, Stefano Rivella, John C. Wood	4
6	Successful quality improvement project to increase hydroxyurea prescriptions for children with sickle cell anaemia 2023 ·BMJ Quality & Safety ·Ofelia Álvarez, (unknown), (unknown), (unknown), Julie Kanter, John J. Strouse, (unknown), Cheryl Courtlandt, (unknown), Ifeyinwa Osunkwo	1
7	Evaluating the Discriminatory Ability of the Sickle Cell Data Collection Program’s Administrative Claims Case Definition in Identifying Adults With Sickle Cell Disease: Validation Study 2023 ·JMIR Public Health and Surveillance ·Ashima Singh, Marci K. Sontag, Mei Zhou, Mahua Dasgupta, Tessa Crume, (unknown), Najibah A. Galadanci, (unknown), (unknown), Amanda M. Brandow, (unknown), (unknown), (unknown), Angela Snyder, Julie Kanter	2
8	What does it mean to be affiliated with care?: Delphi consensus on the definition of “unaffiliation” and “specialist” in sickle cell disease 2022 ·PLoS ONE ·Andrea Lamont, Lewis L. Hsu, Sara Jacobs, Robert W. Gibson, Marsha Treadwell, Yumei Chen, Richard Lottenberg, (unknown), (unknown), Cathy L. Melvin, Sharon Smith, (unknown), Julie Kanter	6
9	Consensus definition of essential, optimal, and suggested components of a pediatric sickle cell disease center 2022 ·Pediatric Blood & Cancer ·Monica L. Hulbert, Deepa Manwani, Emily Riehm Meier, Ofelia Álvarez, R. Clark Brown, Michael U. Callaghan, Andrew Campbell, Thomas D. Coates, Melissa Frei‐Jones, Jane S. Hankins, Matthew M. Heeney, Lewis L. Hsu, Jeffrey D. Lebensburger, Charles T. Quinn, Nirmish Shah, Kim Smith‐Whitley, Courtney D. Thornburg, Julie Kanter	13
10	Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study 2022 ·Blood ·Matthew M. Heeney, Miguel R. Abboud, Jessie Githanga, Baba Inusa, Julie Kanter, Alan D. Michelson, Videlis Nduba, Victor Musiime, (unknown), Adlette Inati, Amar Taksande, Marielle Andersson, Magnus Åstrand, Noha Maklad, Mohammad Niazi, Anders Himmelmänn, Anders Berggren	11
11	Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years 2022 ·Blood Advances ·Mohsen Saleh Elalfy, Mona Hamdy, Amal El‐Beshlawy, Fatma Soliman Elsayed Ebeid, Mohamed Badr, Julie Kanter, Baba Inusa, Amira Adly, Suzan Williams, Yurdanur Kılınç, David D. Lee, Caroline Fradette, (unknown), (unknown), Fernando Tricta, Janet L. Kwiatkowski	16
12	Hemorrhagic Stroke in Children and Adults With Sickle Cell Anemia: The Post-STOP Cohort 2022 ·Stroke ·Christine K. Fox, (unknown), Nancy K. Hills, Janet L. Kwiatkowski, Julie Kanter, John J. Strouse, Jenifer H. Voeks, Heather J. Fullerton, Robert J. Adams, (unknown)	9
13	Resolution of Serious Vaso-Occlusive Pain Crises: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy 2021 ·Transplantation and Cellular Therapy ·Mark C. Walters, Alexis A. Thompson, Markus Y. Mapara, Janet L. Kwiatkowski, Lakshmanan Krishnamurti, Banu Aygün, Kimberly A. Kasow, (unknown), Manfred Schmidt, (unknown), Francis J. Pierciey, (unknown), Ren Chen, Sunita Goyal, Julie Kanter, John F. Tisdale	1
14	Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study 2021 ·Blood Advances ·Janet L. Kwiatkowski, Mona Hamdy, Amal El‐Beshlawy, Fatma Soliman Elsayed Ebeid, (unknown), Abdulrahman Alshehri, Julie Kanter, Baba Inusa, Amira Adly, Suzan Williams, Yurdanur Kılınç, David Lee, Fernando Tricta, Mohsen Saleh Elalfy	33
15	<p>Development of a Severity Classification System for Sickle Cell Disease</p> 2020 ·ClinicoEconomics and Outcomes Research ·Nirmish Shah, David O. Beenhouwer, Michael S. Broder, (unknown), Laura M. De Castro, Sarah N. Gibbs, Victor R. Gordeuk, Julie Kanter, Elizabeth S. Klings, Thokozeni Lipato, Deepa Manwani, (unknown), Irina Yermilov, Wally R. Smith	19
16	Ticagrelor does not impact patient‐reported pain in young adults with sickle cell disease: a multicentre, randomised phase II b study 2018 ·British Journal of Haematology ·Julie Kanter, Miguel R. Abboud, Banu Kaya, Videlis Nduba, (unknown), (unknown), (unknown), Maria Leonsson‐Zachrisson, (unknown)	23
17	Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial) 2018 ·Blood Advances ·Ahmed Daak, Carlton Dampier, Beng Fuh, Julie Kanter, Ofelia Álvarez, (unknown), (unknown), Michael U. Callaghan, Alex George, Lynne Neumayr, Lee Hilliard, (unknown), Adrián L. Rabinowicz, Matthew M. Heeney	31
18	Crizanlizumab 5.0 Mg/Kg Increased the Time to First on-Treatment Sickle Cell Pain Crisis: A Subgroup Analysis of the Phase II Sustain Study 2017 ·Blood ·Julie Kanter, Abdullah Kutlar, Darla Liles, Rodolfo Delfini Cançado, (unknown), Michael Shi, Zewen Zhu, Kenneth I. Ataga	1
19	Vitamin D Insufficiency is a Frequent Finding in Pediatric and Adult Patients with Sickle Cell Disease and Correlates with Markers of Cell Turnover 2014 ·(unknown), Julie Kanter, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	9
20	Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia 2012 ·Blood ·Vivek Patel, Matthieu Mahévas, Soo Yong Lee, Roberto Stasi, Susanna Cunningham–Rundles, Bertrand Godeau, Julie Kanter, Ellis J. Neufeld, Tillmann Taube, Ugo Ramenghi, Shalini Shenoy, Mary J. Ward, Nino Mihatov, (unknown), Philippe Bierling, Martin Lesser, Nichola Cooper, James B. Bussel	243

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact